Irish Dermatologists' Experience With JAK Inhibitors In Alopecia Areata

A survey of 124 Irish dermatologists revealed that 90% have experience using Janus kinase inhibitors (JAKi) for treating alopecia areata (AA), with baricitinib being the most common first choice. The study highlights the variability in treatment practices due to the lack of global guidelines, with 95% of respondents expressing the need for standardized guidelines. Despite the impressive efficacy of JAKi, challenges remain, such as high relapse rates post-treatment cessation and the inability to predict patient response. The survey's low response rate (16.9%) and small sample size limit its generalizability, but it provides valuable insights into current practices and the demand for standardized treatment protocols.